X
Xiaodong Yang
Researcher at Merck & Co.
Publications - 22
Citations - 1040
Xiaodong Yang is an academic researcher from Merck & Co.. The author has contributed to research in topics: Glucagon receptor & Glucagon. The author has an hindex of 17, co-authored 22 publications receiving 905 citations. Previous affiliations of Xiaodong Yang include National Institute on Drug Abuse & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Systemic pan-AMPK activator MK-8722 improves glucose homeostasis but induces cardiac hypertrophy
Robert W. Myers,Hong-Ping Guan,Juliann Ehrhart,Aleksandr Petrov,Srinivasa Prahalada,Effie Tozzo,Xiaodong Yang,Marc M. Kurtz,Maria E. Trujillo,Dinko Gonzalez Trotter,Danqing Feng,Shiyao Xu,George J. Eiermann,Marie A. Holahan,Daniel Rubins,Stacey Conarello,Xiaoda Niu,Sandra C. Souza,Corin O. Miller,Jinqi Liu,Ku Lu,Wen Feng,Ying Li,Ronald E. Painter,James A. Milligan,Huaibing He,Franklin Liu,Aimie Ogawa,Douglas Wisniewski,Rory J. Rohm,Liyang Wang,Michelle Bunzel,Ying Qian,Wei Zhu,Hongwu Wang,Bindu Bennet,Lisa LaFranco Scheuch,Guillermo Fernandez,Cai Li,Michael Klimas,Gaochao Zhou,Margaret van Heek,Tesfaye Biftu,Ann E. Weber,David E. Kelley,Nancy A. Thornberry,Mark D. Erion,Daniel M. Kemp,Iyassu K. Sebhat +48 more
TL;DR: MK-8722 is developed, a potent, direct, allosteric activator of all 12 mammalian AMPK complexes that induced robust, durable, insulin-independent glucose uptake and glycogen synthesis, with resultant improvements in glycemia and no evidence of hypoglycemia in rodents and rhesus monkeys.
Journal ArticleDOI
A Novel Glucagon Receptor Antagonist Inhibits Glucagon-Mediated Biological Effects
Sajjad A. Qureshi,Mari R. Candelore,Dan Xie,Xiaodong Yang,Laurie Tota,Victor D.-H. Ding,Zhihua Li,Alka Bansal,Corin O. Miller,Sheila M. Cohen,Guoqiang Jiang,Ed Brady,Richard Saperstein,Joseph L. Duffy,James R. Tata,Kevin T. Chapman,David E. Moller,Bei B. Zhang +17 more
TL;DR: Compound 1 (Cpd 1) is a potent glucagon receptor antagonist that has the capability to block the effects of glucagon in vivo, and real-time measurement of glycogen synthesis and breakdown in perfused mouse liver showed that Cpd 1 is capable of blocking glucagon-induced glycogenolysis in a dosage-dependent manner.
Journal ArticleDOI
A human synaptic vesicle monoamine transporter cDNA predicts posttranslational modifications, reveals chromosome 10 gene localization and identifies TaqI RFLPs.
Christopher K. Surratt,Antonio M. Persico,Xiaodong Yang,Stephanie R. Edgar,Geoffrey S. Bird,Anita L. Hawkins,Constance A. Griffin,Xiang Li,Ethylin Wang Jabs,George R. Uhl +9 more
TL;DR: The cDNA, and a subclone, recognize TaqI polymorphisms that may prove useful to assess this gene's involvement in neuropsychiatric disorders involving monoaminergic brain systems.
Journal ArticleDOI
Discovery of a novel glucagon receptor antagonist N-[(4-{(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine (MK-0893) for the treatment of type II diabetes.
Yusheng Xiong,Guo Jian,Mari R. Candelore,Rui Liang,Corey Miller,Qing Dallas-Yang,Guoqiang Jiang,Peggy E. McCann,Sajjad A. Qureshi,Xinchun Tong,Shiyao Sherrie Xu,Jackie Shang,Stella H. Vincent,Laurie Tota,Michael Wright,Xiaodong Yang,Bei B. Zhang,James R. Tata,Emma R. Parmee +18 more
TL;DR: Compound 9m blunted glucagon-induced glucose elevation in hGCGR mice and rhesus monkeys and lowered ambient glucose levels in both acute and chronic mouse models.
Journal ArticleDOI
Discovery and investigation of a novel class of thiophene-derived antagonists of the human glucagon receptor.
Joseph L. Duffy,Brian A. Kirk,Zenon Konteatis,Elizabeth Louise Campbell,Rui Liang,Edward J. Brady,Mari R. Candelore,Victor D.-H. Ding,Guoqiang Jiang,Frank Xiaoqing Liu,Sajjad A. Qureshi,Richard Saperstein,Deborah Szalkowski,Sharon Tong,Lauri M. Tota,Dan Xie,Xiaodong Yang,Peter Zafian,Song Zheng,Kevin T. Chapman,Bei B. Zhang,James R. Tata +21 more
TL;DR: Systematic modification of the lead compound identified substituents that were essential for activity and those that were amenable to further optimization that resulted in the synthesis of 13, which exhibited good potency as an hGCGR functional antagonist and moderate bioavailability.